Newsroom

Press Releases

01/31/2013 : The Cutaneous Lymphoma Foundation Launches Research Awards Program

Prestigious New CLARIONS Grant Program Charts Path to Cure Cutaneous Lymphoma

12/09/2012 : Giorgia Saporiti, MD Receives Young Investigator's Award from the Cutaneous Lymphoma Foundation

Dr. Saporiti Received Prestigious Award During the 2012 American Society of Hematology Meeting

07/17/2012 : Cutaneous Lymphoma Foundation Appoints New CEO

The Board of Directors of the Cutaneous Lymphoma is pleased to welcome Susan Thornton as its new CEO.

06/05/2012 : Ceptaris Secures $10 Million in Series D-1 Financing for Mechlorethamine Gel Production

Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced on June 5, 2012 that it has raised $10 million in Series D-1 financing for the operational expenses of producing mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides. Ceptaris has also received a Complete Response Letter from the FDA regarding the New Drug Application (NDA) for the gel.

01/05/2012 : Yaupon Changes Name to Ceptaris Therapeutics, Inc.

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today it has changed its name to Ceptaris Therapeutics, Inc., effective immediately. The new name is intended to reflect the recent changes in management and the Company’s ongoing transformation into a commercial organization. Ceptaris Therapeutics’ lead drug candidate, mechlorethamine gel, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell Lymphoma (CTCL).

08/18/2011 : Judy Jones Transitions to President Emeritus of Cutaneous Lymphoma Foundation

After nearly 14 years of passionate service to patients and others affected by cutaneous lymphoma, Judy Jones, Founder of the Cutaneous Lymphoma Foundation (CLF), has stepped away from daily operations and from her role as President of the Board of Directors.

07/28/2011 : Yaupon Therapeutics, Inc. Submits New Drug Application For Proprietaty Gel Formulation Of Mechlorethamine Hydrochloride

Requesting U.S. marketing approval for the topical treatment of early stage (stages I-IIA) mycosis fungoides, a common type of Cutaneous T-Cell Lymphoma

06/16/2011 : FDA Grants Accelerated Approval of Istodax®

FDA Grants Accelerated Approval of Istodax® As Treatment For Patients With Peripheral T-Cell Lymphoma Who Have Received At Least One Prior Therapy

06/01/2011 : Cutaneous Lymphoma Foundation CEO, Jennifer Viano, Talks with OncUView.tv at the American Society of Clinical Oncology's Annual Meeting

Cutaneous Lymphoma Foundation CEO, Jennifer Viano, Talks with OncUView.tv at the American Society of Clinical Oncology’s Annual Meeting

03/11/2011 : Cutaneous Lymphoma Foundation Featured in USA Today

Judy Jones, President Emeritus of the Cutaneous Lymphoma Foundation and President of the Coalition of Skin Diseases, writes about the burden of skin disease in USA Today